In today’s modern lifestyle, obesity and its diseases are becoming major challenges for public health worldwide. Due to irregular diet and lack of exercise, this disease is increasing rapidly. In view of this, a study done by the scientists of the University of Texas at San Antonio, USA. Study A new treatment for obesity has been claimed in The team of researchers here has developed such an inhibitor, which helps in fighting obesity. Apart from this, it is also effective in the prevention of heart diseases associated with obesity. Associate in the Department of Chemistry in the USTA’s College of Sciences Professor Francis Yoshimoto (Francis K. Yoshimoto) An anti-obesity drug has been developed by a team of scientists led by Dr. U.S., which blocks the absorption of cholesterol and the effect of cytochrome P450 8B1 associated with obesity.
Yoshimoto is an associate of the UTSA College of Health, Community and Policy Department in the trial of this new drug. Professor Eunhee Chung has collaborated. Yoshimoto sent a sample of the synthesis design of this drug to the lab funded by Chung’s National Institute of Health for testing.
in the lab Professor Chung And his research team studied the effect of bioactive mixtures on chemicals found in small amounts in plants and certain foods. Along with this, it was also discovered how obesity and metabolic disturbances can be overcome by exercise. The conclusion of this study is in the medical journal ‘Steroids’. published Has been done.
What happened in the study
The research team gave this inhibitor drug to the rats for seven days. Its results came out that even after being given a diet containing high fat and high sucrose, the level of glucose in the blood of the rats was found to be low. The special thing is that there was no effect on his weight. These results demonstrate how P450 8B1 inhibitors may be beneficial in terms of metabolic profile and in the treatment of obesity and associated diabetes.
How does this inhibitor work?
Developed by UTSA, this medicine has the ability to inhibit the activity of P450 8B1 enzyme, which produces colic acid in the body. This inhibition reduces the absorption of cholesterol. The process could also be used to treat metabolic disorders associated with obesity and diabetes, including heart diseases.